Abstract
Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the development and progression of diabetic micro- and macroangiopathy. Among various metabolic derangements implicated in the pathogenesis of diabetic vascular complication, advanced glycation end product (AGE) hypothesis is most compatible with the theory of hyperglycemic memory. In this review, we discuss the molecular mechanisms of diabetic vascular complication, specially focusing on AGEs and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here.
Keywords: diabetic vascular complications, atherosclerosis, ages, oxidative stress, rage, renin-angiotensin system, insulin resistance, pigment epithelium-derived factor
Current Diabetes Reviews
Title: Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications
Volume: 1 Issue: 1
Author(s): Sho-ichi Yamagishi, Kazuo Nakamura and Tsutomu Imaizumi
Affiliation:
Keywords: diabetic vascular complications, atherosclerosis, ages, oxidative stress, rage, renin-angiotensin system, insulin resistance, pigment epithelium-derived factor
Abstract: Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the development and progression of diabetic micro- and macroangiopathy. Among various metabolic derangements implicated in the pathogenesis of diabetic vascular complication, advanced glycation end product (AGE) hypothesis is most compatible with the theory of hyperglycemic memory. In this review, we discuss the molecular mechanisms of diabetic vascular complication, specially focusing on AGEs and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Nakamura Kazuo and Imaizumi Tsutomu, Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications, Current Diabetes Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573399052952631
DOI https://dx.doi.org/10.2174/1573399052952631 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Activity of Uva di Troia Canosina: Comparison of Two Extraction Methods
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Electrochemical Detection and Sensing of Reactive Oxygen Species
Current Organic Chemistry Recent Advances on 3-Hydroxyflavone Derivatives: Structures and Properties
Mini-Reviews in Medicinal Chemistry Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification
Current Drug Targets Clinical Aspects of Tumor Necrosis Factor-α Signaling in Hepatocellular Carcinoma
Current Pharmaceutical Design Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema
Current Pharmaceutical Design Development of Functional Dark Chocolate by Incorporating Flaxseed (Linum usitatissimum) Oil and Honey with Improved Organoleptic and Textural Attributes
Current Nutrition & Food Science Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets EDITORIAL [Hot Topic-I: Molecular and Pharmacological Aspects of Existing and Experimental Bone Anabolic Therapies (Guest Editor: Naibedya Chattopadhyay)]
Current Molecular Pharmacology Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Meet Our Editorial Board Member
Current Clinical Pharmacology subject Index To Volume 3
Current Protein & Peptide Science Physiological and Pathophysiological Functions of SIRT1
Mini-Reviews in Medicinal Chemistry Highly Selective MEK Inhibitors
Current Enzyme Inhibition Type 2 Diabetes and Oral Antihyperglycemic Drugs
Current Medicinal Chemistry Patent Selections:
Recent Patents on Biomarkers Intrauterine Growth Restriction in Singleton Pregnancy-Surveillance and Delivery: An Overview
Current Women`s Health Reviews